A day after scientists announced that mRNA vaccines are effective against the Delta variant of Covid-19, a single dose variant of Russia's Sputnik-V vaccine has shown 94 per cent efficacy among those recovered Covid-19 patients. Scientists said that there is no evident benefit of using a second dose in previously infected individuals.
However, they added, "the second dose further increases antibody and neutralising capacity."
The study published in the journal Science Direct states that 21 days after receiving the first dose of vaccine, 94 per cent of participants developed spike-specific antibodies. The study was conducted among healthcare workers in Argentina.
"A single Sputnik V dose elicits higher antibody levels and virus neutralising capacity in previously infected individuals than in new ones receiving the full two-doses," researchers said.